Vogenx Inc.
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is…
1D
-9.5%
1W
-17.3%
1M
-56.5%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
17/12/2026 (in 61 days)
Volatility around earnings
Not enough history for an assessment
FREE FLOAT
64.3%
FLOAT SHARES
9,544,928
AVG. DAILY VOLUME (30D)
130,861
DELMAR STEVEN R
Pieraccini Peter
Vogenx Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is James Green, the company employs around 4 people.
The IPO was on 12/08/2026; the stock trades on NASDAQ under the ticker VOGX.
The next earnings date is 17/12/2026.
No, Vogenx currently does not pay a dividend.
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
Clicking "Analyze stock" lets five strategies assess Vogenx against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.